Abstract
Since the end of 2020, the mass vaccination has been actively promoted and seemed to be effective to bring the COVID-19 pandemic under control. However, the fact of immunity waning and the possible existence of antibody-dependent enhancement (ADE) make the situation uncertain. We developed a dynamic model of COVID-19 incorporating vaccination and immunity waning, which was calibrated by using the data of accumulative vaccine doses administered and the COVID-19 epidemic in 2020 in mainland China. We explored how long the current vaccination program can prevent China in a low risk of resurgence, and how ADE affects the long-term trajectory of COVID-19 epidemics. The prediction suggests that the vaccination coverage with at least one dose reach 95.87%, and with two-doses reach 77.92% on August 31, 2021. However, even with the mass vaccination, randomly introducing infected cases in the post-vaccination period can result in large outbreaks quickly in the presence of immunity waning, particularly for SARS-CoV-2 variants with higher transmission ability. The results showed that with the current vaccination program and a proportion of 50% population wearing masks, mainland China can be protected in a low risk of resurgence till 2023/01/18. However, ADE effect and higher transmission ability for variants would significantly shorten the protective period for more than 1 year. Furthermore, intermittent outbreaks can occur while the peak values of the subsequential outbreaks are decreasing, meaning that subsequential outbreaks boosted the immunity in the population level, which further indicating that catching-up vaccination program can help to mitigate the possible outbreaks, even avoid the outbreaks. The findings reveal that integrated effects of multiple factors, including immunity waning, ADE, relaxed interventions, and higher transmission ability of variants, make the control of COVID-19 much more difficult. We should get ready for a long struggle with COVID-19, and should not totally rely on COVID-19 vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is supported by the National Natural Science Foundation of China (grant numbers: 12031010(ST),11631012(YX),12001349(WZ)), the Postdoctoral Research Foundation of China (grant number: 2019M663611 (WZ)), and the Young Talent Support Plan of Xi'an Jiaotong University (BT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data were released and analysed anonymously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The epidemic data is public available.
